ProPhase Labs (NASDAQ:PRPH) Stock Crosses Above Two Hundred Day Moving Average of $5.00

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.00 and traded as high as $5.17. ProPhase Labs shares last traded at $4.90, with a volume of 62,087 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of ProPhase Labs in a research report on Wednesday, February 21st.

ProPhase Labs Stock Performance

The stock has a 50-day moving average of $5.54 and a 200-day moving average of $5.00. The firm has a market cap of $91.33 million, a price-to-earnings ratio of -5.16 and a beta of -0.29. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.10 and a current ratio of 2.28.

ProPhase Labs (NASDAQ:PRPH) last announced its earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. The firm had revenue of $3.50 million during the quarter, compared to analyst estimates of $10.71 million. As a group, analysts anticipate that ProPhase Labs, Inc. will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PRPH. HighTower Advisors LLC acquired a new position in shares of ProPhase Labs during the 3rd quarter worth approximately $756,000. SVB Wealth LLC acquired a new position in shares of ProPhase Labs during the 3rd quarter worth approximately $208,000. Finally, Tower Research Capital LLC TRC increased its position in shares of ProPhase Labs by 50.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after purchasing an additional 5,026 shares during the last quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.